Table 2 Least squares mean change in primary and secondary clinical outcomes in mixed-effects model repeated measurement statistical analysis
From: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
At week 104 | Placebo | Gantenerumab 105 mg | Gantenerumab 225 mg | ||
|---|---|---|---|---|---|
LS mean (95% CI) | LS mean (95% CI) | p Value vs placebo | LS mean (95% CI) | p Value vs placebo | |
Primary endpoint | |||||
CDR-SB | |||||
Change from baseline | 1.60 (1.28, 1.91) | 1.69 (1.37, 2.01) | – | 1.73 (1.42, 2.04) | – |
Difference from placebo | – | 0.10 (−0.35, 0.54) | 0.67 | 0.18 (−0.28, 0.63) | 0.45 |
Secondary endpoint | |||||
ADAS-Cog 13 | |||||
Change from baseline | 5.77 (4.54, 6.99) | 5.14 (3.91, 6.38) | – | 5.54 (4.21, 6.87) | – |
Difference from placebo | – | −0.62 (−2.34, 1.09) | 0.48 | −0.27 (−2.23, 1.70) | 0.79 |
FAQ | |||||
Change from baseline | 4.70 (3.71, 5.68) | 5.93 (4.93, 6.93) | – | 4.57 (3.58, 5.55) | – |
Difference from placebo | – | 1.23 (−0.16, 2.62) | 0.08 | −0.27 (−1.72, 1.18) | 0.72 |
MMSE | |||||
Change from baseline | −2.93 (−3.50, −2.35) | −3.02 (−3.60, −2.44) | – | −2.73 (−3.33, −2.14) | – |
Difference from placebo | – | −0.10 (−0.90, 0.71) | 0.81 | 0.34 (−0.54, 1.22) | 0.45 |